Omeros has an amazing pipeline of medical advances, yet the company is valued at around $125 million. Their GPCR unlocking effort is what really fascinates me. They're identifying pathways to develop drugs for significant ailments/afflictions for which there are no drugs available today.
IMO OMER is poorly understood and underpriced.